Search Results

Eric Trinquet, a veteran innovator behind functional GPCR assays like HTRF and IP-One, believes rigid “You can try, try, try—and fail, fail, fail,” Eric says. Instead of chasing linear progress, Eric encourages young scientists to stay playful longer—embracing Eric and his team rejected the calcium route entirely. Eric is clear: real innovation requires real partnerships.

Eric Trinquet, Director of Research and Development at Revvity.   Eric Trinquet  to the Dr. precision reagents and validated assay platforms. 🔍 Learn More → Listen to the Podcast with Revvity’s Eric

Exploring the foundational stages of scientific breakthroughs with Eric Trinquet, highlighting that true Eric Trinquet shares what it really takes to bring a product to life—from sketch to shelf. Eric Trinquet joined Cisbio in the early 2000s, working on what would become HTRF—Homogeneous Time-Resolved Eric Trinquet The Real Work Starts Before the Lab What most scientists don’t see is how long a product

Eric Trinquet, that moment arrived when his team successfully tracked GPCR internalization in native That’s the promise of pHSense, a groundbreaking reagent developed by Eric Trinquet and his team at Revvity Eric Trinquet.

Eric Trinquet, the scientist behind IP-One, Tag-lite, and now pHSense, challenges conventional scientific From failing fast to embracing serendipity, Eric shares the mindset (and messy origin stories) that shaped

Eric Trinquet shares in a special Dr.

Eric Trinquet traces how a series of bold pivots—from Cisbio’s HTRF platform to IP-One and now pHSense—reshaped

Addex Provides Corporate Update And Financial Guidance Structure Therapeutics Appoints Industry Leaders Eric

Eric Trinquet and his team at Revvity, that moment came when they watched GPCRs internalize in native

employed in GPCRs mediated signal transduction.[47] The 2000 Nobel Prize in Physiology or Medicine went to Eric Eric R.